Annual report pursuant to Section 13 and 15(d)

Organization and Summary of Significant Accounting Policies (Narrative) (Details)

v3.3.1.900
Organization and Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Jan. 31, 2015
Aug. 31, 2011
Organization And Summary Of Accounting Policies [Line Items]            
Fair value of notes payable   $ 64,000,000 $ 37,900,000      
Notes payable   61,100,000 33,800,000      
Derivative liabilities   63,000 0      
Impairment of long-lived assets   $ 0 0 $ 0    
Non-refundable upfront cash payment received $ 2,000,000          
Deferred revenue recognition period   2 years        
Liability for uncertain tax positions   $ 0 0      
Deferred debt issuance cost     90,000      
Notes Payable Current [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Notes payable, discounts   0 863,813      
Notes Payable Current [Member] | New Accounting Pronouncement, Early Adoption, Effect [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Notes payable, discounts   35,000        
Notes Payable Non Current [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Notes payable, discounts   2,033,506 $ 1,585,882      
Notes Payable Non Current [Member] | New Accounting Pronouncement, Early Adoption, Effect [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Notes payable, discounts   $ 55,000        
The 2002 and 2014 Plan [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Stock based compensation, outstanding stock options' expiration period   10 years        
Stock based compensation, outstanding stock options' expiration period upon optionee's separation from employment   90 days        
Minimum [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Estimated useful lives, patent costs   5 years        
Minimum [Member] | The 2002 and 2014 Plan [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Stock based compensation, granted stock options' vesting period   1 year        
Maximum [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Estimated useful lives, patent costs   15 years        
Maximum [Member] | The 2002 and 2014 Plan [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Stock based compensation, granted stock options' vesting period   4 years        
The 2002 Plan [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Total number of shares authorized   12,000,000        
The 2014 Plan [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Total number of shares authorized   5,000,000        
GDS Business [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Cash received in exchange for the assets of GDS business           $ 30,300,000
Royalty receivable through 2017           $ 20,000,000
Net income related to royalty amounts earned   $ 759,000        
Royalty payments received   1,200,000        
Estimated amount of tax   $ 436,000        
Macrophage Therapeutics, Inc. [Member]            
Organization And Summary Of Accounting Policies [Line Items]            
Ownership percentage         99.90%